Neurokinin 1 receptor antagonism as a possible therapy for alcoholism - sprookjes - yvandenbroek - TriplyDB

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

http://www.wikidata.org/entity/Q28268781

about

The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked?Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse The pharmacology of neurokinin receptors in addiction: prospects for therapy Gut-brain peptides in corticostriatal-limbic circuitry and alcohol use disorders Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.A differential role for neuropeptides in acute and chronic adaptive responses to alcohol: behavioural and genetic analysis in Caenorhabditis elegans Medications for unhealthy alcohol use: across the spectrum.A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.Nicotine Enhances Excitability of Medial Habenular Neurons via Facilitation of Neurokinin Signaling A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress.Medication treatment of different types of alcoholism.Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence.Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial.Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence.Involvement of substance P and the NK-1 receptor in human pathology.Ethanol-enhanced GABA release: a focus on G protein-coupled receptors.Methods for inducing alcohol craving in individuals with co-morbid alcohol dependence and posttraumatic stress disorder: behavioral and physiological outcomes Addiction research centres and the nurturing of creativity: the National Institute on Alcohol Abuse and Alcoholism.Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.Neuroimmune pathways in alcohol consumption: evidence from behavioral and genetic studies in rodents and humans Stability of fMRI striatal response to alcohol cues: a hierarchical linear modeling approach.Genetic association of the tachykinin receptor 1 TACR1 gene in bipolar disorder, attention deficit hyperactivity disorder, and the alcohol dependence syndrome Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis.An acute psychosocial stressor increases drinking in non-treatment-seeking alcoholics.An acute psychosocial stressor does not potentiate alcohol cue reactivity in non-treatment-seeking alcoholics.A novel role for PSD-95 in mediating ethanol intoxication, drinking and place preference.Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study Quantification of central substance P receptor occupancy by aprepitant using small animal positron emission tomography.Stress-induced reinstatement of alcohol-seeking in rats is selectively suppressed by the neurokinin 1 (NK1) antagonist L822429.Translational and reverse translational research on the role of stress in drug craving and relapse.

P2860

Q21089996-B08FF9B8-9AF5-4006-9B39-F7283F1C76B7 Q22241964-7C713D6A-0A17-4617-8B91-6EFC0E7EBD68 Q24600288-B02A1C10-5101-42D2-8BFD-EA8490D82C53 Q24633835-ABAAF257-5476-4E82-A0AC-D61AED6EE509 Q26785438-A0763D29-D648-4385-8227-8BD1629D7637 Q27014840-FF99EFD3-3B94-4A24-91FE-A62F468A421A Q27014879-97F174B8-8E7D-4C12-8BD3-0B1D161BB19A Q27330029-66F16812-1DAE-4905-8078-E38EA60D5067 Q27690692-8AE5A094-D9C9-49C7-A403-077C497ACBEC Q28068256-DB6CB4EF-202C-4A5E-9F55-5983D5CD78E1 Q29028895-DF8D4C39-419C-4FEB-BEAC-109951036670 Q30275691-3046B2B9-B660-45E3-97F3-EA15E7232E83 Q30366964-AC87FE45-6BE6-475F-BD41-C1B5AD7790C1 Q30434793-26AABF4D-0734-48B1-93E8-3AF27DF50DE4 Q30436640-0DBD5ED0-0686-4763-A090-6804DE2DFFAC Q30447847-11B2B06E-521A-4057-BDF5-34D51F456B4E Q30479172-059F0AE1-1FF9-496F-8581-DC5CF08AB054 Q30497060-87F3FAE7-4F8D-4742-B93D-7F87C3DB4E14 Q33815691-52710EF7-682A-4180-B46C-4FE52E01E3E6 Q33940215-96CFC2A8-8181-401F-B7CC-ADCB803CB463 Q34157073-BF0F6C4A-C9EE-44D6-AEB4-41563B126191 Q34342747-F2502380-6973-491D-B6C8-E4DD2D0DD6A3 Q34413850-4891A595-91C7-49BD-85C4-8946F88D5E70 Q34424216-4BEEB76B-FCB5-48EE-9654-920C5AA62695 Q34474128-2D29B1D0-EA92-4614-A7B3-B655A1A17295 Q34507655-935C088C-783D-4C44-AD9F-4CA8FAC34452 Q34556427-A26AC2D0-41A1-4234-98B4-4AA2BA4CF863 Q34687635-6C284129-E062-4CB7-8E9B-17B805C27B4E Q34733307-B039291F-8257-4FEB-85B5-D36A85BB05F0 Q34782251-FF39F30D-B043-41AA-9D25-E389D6AB0BFD Q34798686-72BD175A-9F25-4D20-BBA4-97273DB77AC8 Q35032821-FF87C3AA-E98E-4588-8B1C-EAF9B8C01D58 Q35046485-42AB7FF2-4466-4EE2-A74D-CE2E931D82D9 Q35053295-FB92A575-DAA1-4480-9159-AB77FE079005 Q35147998-BC9B45D8-5584-44E0-8340-7CDEF140E131 Q35162929-0F749E40-A3A5-4957-B83A-970041C71FDE Q35200032-04193E71-271B-48BE-86BC-EB2F435255B1 Q35203652-3BF93FB9-2617-4CE9-85BE-7DA6AAA2BB2B Q35332004-B53EB6A2-1D8A-4967-8C5B-40C3D062F648 Q35332832-9C06CDFA-E8F0-43E1-A6F9-76293327DEA7

P2860

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

http://www.wikidata.org/entity/Q28268781

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

@ast

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

@en

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

@nl

type

label

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

@ast

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

@en

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

@nl

prefLabel

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

@ast

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

@en

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

@nl

P1433

Q28268781-2A7F0B60-AC6B-452E-8A00-79B77D027313

P1476

Q28268781-9468810F-C20F-45E9-9906-818652DD1BE7

P2093

Q28268781-086DEA06-FAF7-4958-867B-3FEB935341EA

Q28268781-1DBB7EB5-B6AC-4BAB-94BD-9F7657F17A81

Q28268781-2CDFE6DD-8243-4B46-8DFC-3ACBF9BFC85D

Q28268781-39D7215C-577F-401F-AEC3-14FAE475AC67

Q28268781-45CBD27D-8638-459E-A730-A3746201C0FE

Q28268781-78FEA724-5158-4231-94FF-D692075EB167

Q28268781-942133A5-9227-4F4A-B844-31901B70CF9A

Q28268781-9EC460AE-12C3-42ED-95F1-0FEE61429609

Q28268781-D31F3E7A-8D26-43E0-BF4F-1E520B56FC07

Q28268781-DB3EB91F-36C0-4F39-AB44-5879EC36238C

P2860

Q28268781-18F09A04-E388-4A4B-ABAA-0648AFD5F1D9

Q28268781-2347A7AF-0092-4CE7-8984-E82688B67902

Q28268781-33B0081E-3FBC-49B1-8F37-3B64B9DF894E

Q28268781-37255CE2-422A-4E6B-A7E2-B3B681F2A89F

Q28268781-439C74BF-BED9-4AFE-A30F-7E2822E08B3B

Q28268781-468890A0-21C0-459B-A428-94E31B7ADA25

Q28268781-4FD1F191-83F6-4DAB-8468-ECA3DB1452C6

Q28268781-53E5940C-B98A-42B0-85B5-1ABDD6E9BFDD

Q28268781-5B34F44C-A912-4957-9984-23008404408F

Q28268781-5F58C4E2-832A-412C-BC79-F54B017F00CB

P304

Q28268781-E840021D-CE9D-40B1-8BAC-BA9341F5415A

P31

Q28268781-D519F983-792F-4E21-A420-4B31AD0505DE

P356

Q28268781-76544275-8FCC-41CB-8BD8-7496162CADD2

P407

Q28268781-9B28A835-6C96-4448-A73E-58874BD1099C

P433

Q28268781-15560CBE-8D13-4613-87E0-830E71D7FC91

P478

Q28268781-ED456C03-3CCD-48E3-8202-D1143EC6236F

P50

Q28268781-97F975B3-BB20-410C-9E32-7EAD484DEAF3

P577

Q28268781-A153175B-2918-4F2D-AC0F-0E3D4DCC5DAA

P5875

Q28268781-28821D23-B3AC-48E3-B0AA-98287649603F

P698

Q28268781-85B204CC-AE06-4DA0-BB8B-256219DE9E09

P921

Q28268781-B1EAFC95-EE1F-4E23-8C68-C08C7D3DF3FB

P356

SCIENCE.1153813

P1433

P1476

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

@en

P2093

Christopher Geyer

http://www.w3.org/2001/XMLSchema#string

Daniel Hommer

http://www.w3.org/2001/XMLSchema#string

David Herion

http://www.w3.org/2001/XMLSchema#string

David T George

http://www.w3.org/2001/XMLSchema#string

Donald R Gehlert

http://www.w3.org/2001/XMLSchema#string

Jacqueline Hersh

http://www.w3.org/2001/XMLSchema#string

Jodi Gilman

http://www.w3.org/2001/XMLSchema#string

Johannes T Tauscher

http://www.w3.org/2001/XMLSchema#string

John E Brandt

http://www.w3.org/2001/XMLSchema#string

Markus Heilig

http://www.w3.org/2001/XMLSchema#string

P2860

Altered nociception, analgesia and aggression in mice lacking the receptor for substance P

Damage to the insula disrupts addiction to cigarette smoking

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

Selected major risk factors and global and regional burden of disease

Imaging stress- and cue-induced drug and alcohol craving: association with relapse and clinical implications.

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo.

Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.

The search for genes contributing to the low level of response to alcohol: patterns of findings across studies.

Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.

A key role for corticotropin-releasing factor in alcohol dependence

P304

1536-1539

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.1153813

http://www.w3.org/2001/XMLSchema#string

P407

P433

5869

http://www.w3.org/2001/XMLSchema#string

P478

319

http://www.w3.org/2001/XMLSchema#string

P50

Annika Thorsell

P577

2008-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5574924

http://www.w3.org/2001/XMLSchema#string

P698

18276852

http://www.w3.org/2001/XMLSchema#string

P921